Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Netherlands Cancer Institute
Canadian Cancer Trials Group
National Cancer Institute (NCI)
University of Washington
Immatics US, Inc.
Bristol-Myers Squibb
Regeneron Pharmaceuticals
Pfizer
Biofrontera Inc.
Iovance Biotherapeutics, Inc.
Soligenix
NRG Oncology
Regeneron Pharmaceuticals
Amgen
Almirall, S.A.
Merck Sharp & Dohme LLC
Sun Pharmaceutical Industries Limited
European Organisation for Research and Treatment of Cancer - EORTC
Aura Biosciences
Pfizer
Erasca, Inc.
Eastern Cooperative Oncology Group
Immunocore Ltd
Sandoz
Sun Pharmaceutical Industries Limited
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
IDEAYA Biosciences
Merck Sharp & Dohme LLC
University of Sao Paulo
University Hospital Erlangen
VA Office of Research and Development
mAbxience Research S.L.
Amgen
Bristol-Myers Squibb
Mashhad University of Medical Sciences
Hospices Civils de Lyon
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Hospices Civils de Lyon
Philogen S.p.A.
Karolinska University Hospital
University of Pittsburgh
ETOP IBCSG Partners Foundation
University Hospital, Lille
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
Polynoma LLC